High-Tech-Gründerfonds, the Germany state- and corporate-backed fund, and the Thüringen Foundation for Technology Innovation, and Research [Stift] have invested €700,000 ($1m) in JeNaCell, a biomaterial spin-off of the Friedrich Schiller University Jena (FSU), on 12 October.

JeNaCell’s biomaterial (pictured) can be used for making medical and cosmetic products, suitable for treating poorly healing wounds, as well having applications for wellness products and technology, the company said.

Martin Pfister, investment manager of High-Tech Gründerfonds, said: “JeNaCell’s developments not only in modifiable biomaterials but also in innovative production methods make the company an attractive partner for established providers on the market, especially in the area of active wound management.”

Sven Günther, chief executive of Stift,said: “In co-financing JeNaCell, we’re happy to support an especially innovative and promising business formation project that addresses internationally attractive market segments with effective production technology. JeNaCell shows how a highly qualified team can achieve the extraordinary when…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?